FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease
Similar Posts
Artificial Intelligence for Drug Development
FDA recognizes the increased use of AI throughout the drug development process and across a range of therapeutic areas. Learn more.CDER Nitrosamine Impurity Acceptable Intake Limits
Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs); Updated InformationHimGo may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use HimGo, a product promoted and sold for sexual enhancement on various websites, including ebay.com, and possibly in some retail stores.CDER Data Standards Program
CDER Data Standards ProgramGenzyme Ireland Limited – 01/17/2025
Genzyme Ireland Limited – 01/17/2025. Country: Ireland. Record Type: 483Recommendations for Complying With Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs
This guidance provides recommendations for how requestors can comply with the requirements described in the Proposed Administrative Order titled Over-the-Counter Monograph Procedure for Minor Changes C001: Minor Changes to Solid Oral Dosage Forms for Certain Over-the-Counter Monograph Drugs.